Soleno Therapeutics (SLNO) Total Current Liabilities (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Total Current Liabilities data on file, last reported at $200000.0 in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 98.73% year-over-year to $200000.0 in Q1 2026; TTM through Mar 2026 was $200000.0, a 98.73% decrease from a year earlier, with the FY2025 full-year figure at $61.4 million, up 227.32% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $200000.0, down from $61.4 million in the prior quarter.
• Over the last five years, Total Current Liabilities for SLNO reached as high as $61.4 million in Q4 2025 and fell as low as $200000.0 in Q1 2026.
• Historically, Total Current Liabilities has averaged $16.1 million across 5 years, with a median of $11.5 million in 2023.
• Across the five-year window, Total Current Liabilities soared 294.89% in 2023 and tumbled 98.73% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $7.3 million in 2022, then soared by 57.32% to $11.5 million in 2023, then surged by 62.95% to $18.7 million in 2024, then soared by 227.32% to $61.4 million in 2025, then plunged by 99.67% to $200000.0 in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $200000.0 in Q1 2026, $61.4 million in Q4 2025, and $33.3 million in Q3 2025.